Modulators of G-Protein Coupled Receptors
US-2024383960-A1 · Nov 21, 2024 · US
Thioamide-modified peptides and uses thereof
US10189884B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10189884-B2 |
| Application number | US-201515305681-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2015 |
| Priority date | Apr 28, 2014 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention includes a thioamide-modified peptide, wherein the thioamide modification increases the in vivo half-life of the peptide. The invention further includes methods of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a thioamide-modified peptide of the invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A peptide comprising the thioamide-modified amino acid sequence of SEQ ID NO:2, or a salt or solvate thereof, wherein residue 1 of SEQ ID NO:2 is the N-terminus residue of the peptide. 2. A pharmaceutical composition comprising at least one peptide of claim 1 and a pharmaceutically acceptable carrier. 3. The composition of claim 2 , further comprising at least one additional agent useful for treating or preventing a disease or disorder in a subject. 4. The composition of claim 3 , wherein the disease or disorder comprises at least one selected from the group consisting of diabetes and obesity. 5. The peptide of claim 1 , wherein the C-terminus of the peptide is amidated. 6. The peptide of claim 1 , wherein the C-terminus of the peptide is esterified. 7. The peptide of claim 1 , wherein at least one NH group in the peptide backbone is methylated. 8. The peptide of claim 1 , wherein the N-terminus amino group is methylated or acetylated.
Assignees
Inventors
Classifications
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents · CPC title
Glucagons · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
- C07K14/605Primary
Glucagons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10189884B2 cover?
- The invention includes a thioamide-modified peptide, wherein the thioamide modification increases the in vivo half-life of the peptide. The invention further includes methods of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a thioamide-modified peptide of the invention.
- Who is the assignee on this patent?
- Univ Pennsylvania, Harvard College
- What technology area does this patent fall under?
- Primary CPC classification C07K14/605. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).